|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:approvalYear
|
2018
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01EB07
|
|
gptkbp:brand
|
gptkb:Vizimpro
|
|
gptkbp:CASNumber
|
1110813-31-4
|
|
gptkbp:contraindication
|
hypersensitivity to dacomitinib
|
|
gptkbp:developer
|
gptkb:Pfizer
|
|
gptkbp:eliminationHalfLife
|
70 hours
|
|
gptkbp:hasMolecularFormula
|
C24H25ClFN5O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dacomitinib
|
|
gptkbp:indication
|
EGFR-mutated NSCLC
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
irreversible inhibitor of EGFR
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
469.94 g/mol
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:proteinBinding
|
98%
|
|
gptkbp:PubChem_CID
|
24776411
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
pruritus
weight loss
alopecia
rash
dry skin
decreased appetite
stomatitis
paronychia
|
|
gptkbp:target
|
gptkb:EGFR
|
|
gptkbp:UNII
|
Q1J0B9J7U1
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
|
|
gptkbp:bfsParent
|
gptkb:Non-Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
6
|